0001493152-21-013140.txt : 20210630 0001493152-21-013140.hdr.sgml : 20210630 20210528061509 ACCESSION NUMBER: 0001493152-21-013140 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncotelic Therapeutics, Inc. CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 FORMER COMPANY: FORMER CONFORMED NAME: MATEON THERAPEUTICS INC DATE OF NAME CHANGE: 20160613 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 CORRESP 1 filename1.htm

May 28, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attn: Dillon Hagius

	RE:	Oncotelic Therapeutics, Inc. (CIK: 0000908259)
		Registration Statement No. 333-256448 on Form S-1 (the “Registration Statement”)

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Oncotelic Therapeutics, Inc. hereby requests the acceleration of the effective date of the above referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, June 2, 2021, or as soon thereafter as practicable.

Oncotelic Therapeutics, Inc.

By:	/s/ Vuong Trieu
Name:	Vuong Trieu
Title:	Chief Executive Officer